Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Minden

Showing results (91-100 of 308) with videos related to

Pageof 31
Sort By:
Blood|July 20, 2002
Heterozygous PU.1 mutations are associated with acute myeloid leukemiaBeatrice U Mueller, Thomas Pabst, Motomi Osato, et al.
Cancer Research|September 23, 2022
Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of StemnessAlex C H Liu, Severine Cathelin, Yitong Yang, et al.
Blood Cancer Journal|June 21, 2018
Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemiaIsabelle Laverdière, Meaghan Boileau, Andrea L Neumann, et al.
Blood|February 14, 2003
Heterozygous PU.1 mutations are associated with acute myeloid leukemiaBeatrice U Mueller, Thomas Pabst, Motomi Osato, et al.
American Journal of Hematology|August 19, 2007
Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapyJoseph M Brandwein, Vikas Gupta, Andre C Schuh, et al.
Chemistry & Biology|April 26, 2011
Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cellsSonali B Fonseca, Mark P Pereira, Rida Mourtada, et al.
Blood Cancer Discovery|February 10, 2025
SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated CytotoxicityEnoch Tin, Sergio Rutella, Ismat Khatri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapySteven M Kornblau, Mark D Minden, David B Rosen, et al.
Journal of Medicinal Chemistry|December 14, 2011
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activityBrent D G Page, Haytham Khoury, Rob C Laister, et al.
Molecular Therapy. Methods & Clinical Development|December 10, 2016
Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AMLJu Huang, Yuanfeng Liu, Bryan C Au, et al.
Pageof 31

Showing results (91-100 of 308) with videos related to

Sort By:
Pageof 31
Blood|July 20, 2002
Heterozygous PU.1 mutations are associated with acute myeloid leukemiaBeatrice U Mueller, Thomas Pabst, Motomi Osato, et al.
Cancer Research|September 23, 2022
Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of StemnessAlex C H Liu, Severine Cathelin, Yitong Yang, et al.
Blood Cancer Journal|June 21, 2018
Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemiaIsabelle Laverdière, Meaghan Boileau, Andrea L Neumann, et al.
Blood|February 14, 2003
Heterozygous PU.1 mutations are associated with acute myeloid leukemiaBeatrice U Mueller, Thomas Pabst, Motomi Osato, et al.
American Journal of Hematology|August 19, 2007
Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapyJoseph M Brandwein, Vikas Gupta, Andre C Schuh, et al.
Chemistry & Biology|April 26, 2011
Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cellsSonali B Fonseca, Mark P Pereira, Rida Mourtada, et al.
Blood Cancer Discovery|February 10, 2025
SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated CytotoxicityEnoch Tin, Sergio Rutella, Ismat Khatri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapySteven M Kornblau, Mark D Minden, David B Rosen, et al.
Journal of Medicinal Chemistry|December 14, 2011
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activityBrent D G Page, Haytham Khoury, Rob C Laister, et al.
Molecular Therapy. Methods & Clinical Development|December 10, 2016
Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AMLJu Huang, Yuanfeng Liu, Bryan C Au, et al.
Pageof 31